IFNG and breast carcinoma: In a study relying on MHC I prediction for the identification of NeoAg among mutations found in murine B16 melanoma, CT26 colorectal, and 4T1 mammary carcinoma models, 21%–45% of filtered mutations were immunogenic and elicited T cell IFN-γ production; however, only 2%–13% of these were MHC I-restricted (69).